Brief: Biovica: DiviTumTKa Shows Strong Capabilities In Malignant Melanoma

Biovica International AB

20/05/2021 07:05

May 20 (Reuters) - Biovica International AB  BIOVICb.ST :
    * BIOVICA’S DIVITUMTKA SHOWS STRONG CAPABILITIES IN
MALIGNANT
MELANOMA
    * THESE RESULTS FROM A NEW STUDY AT KAROLINSKA UNIVERSITY
HOSPITAL
WILL BE PRESENTED AT UPCOMING ASCO ANNUAL MEETING, JUNE 4-8,
2021.
    * DIVITUMTKA SHOWS PROGNOSTIC AND PREDICTIVE CAPABILITIES IN
METASTATIC CUTANEOUS MELANOMA PATIENTS UNDERGOING IMMUNOTHERAPY.
    * STUDY RESULTS DEMONSTRATE THAT IN PATIENTS TREATED WITH
IMMUNE
CHECKPOINT INHIBITORS, THOSE WITH LOW TKA HAD MORE THAN 25
PERCENT HIGHER RESPONSE RATE THAN THOSE WITH HIGH TKA.
    * FURTHERMORE, PFS AND OS WAS SIGNIFICANTLY LONGER (19.9 AND
>60
MONTHS VERSUS. 12.6 AND 18.5 MONTHS, RESPECTIVELY) IN PATIENTS
WITH LOW VERSUS. HIGH TKA.

Source text for Eikon:  ID:nMFN2wcQQq 
Further company coverage:  BIOVICb.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;  +48 587696600;))